[Molecular diagnostics in lung carcinoma for therapy stratification]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung cancer is a leading cause of cancer death globally.
• Epidermal growth factor receptor (EGFR) is a key target in non-small cell lung carcinoma (NSCLC).
• EGFR overexpression drives tumor progression, making it a target for therapies like Gefitinib and Erlotinib.

Purpose of the Study:

• To determine the clinical significance of predicting patient response to EGFR-targeted therapies.
• To investigate the role of specific genetic mutations in EGFR-TKI efficacy and resistance.
• To highlight the importance of predictive molecular diagnosis for patient stratification in lung cancer.

Main Methods:

• Review of recent studies on EGFR mutations and their correlation with treatment outcomes.
• Analysis of genetic markers associated with primary and secondary resistance to EGFR-TKI.
• Discussion of the utility of histological material for predictive diagnosis.

Main Results:

• EGFR-mutated tumors show significantly better response and prolonged progression-free survival with EGFR-TKI therapy.
• Key resistance mutations (e.g., KRAS, EGFR T790 M, MET amplification) have been identified.
• EGFR-TKI therapy demonstrates efficacy even as a first-line treatment in patients with specific mutations.

Conclusions:

• Predictive diagnosis of EGFR mutations is essential for effective patient stratification in lung cancer.
• Understanding resistance mechanisms is critical for optimizing EGFR-TKI therapy.
• Molecular profiling is becoming indispensable for personalized lung cancer treatment.